NHS England to fund Duodopa

News

Author: Parkinson's Life editorsPublished: 28 August 2015

Prep: Cook: Serves:

The NHS in England has announced they will fund Duodopa – a life-changing drug for people with advanced Parkinson’s – after campaigners managed to garner the support of nearly a hundred MPs who signed a petition.

This means that should a specialist Parkinson’s clinician prescribe Duodopa, a patient will be able to receive it without delay. Duodopa can help to control the symptoms of advanced Parkinson’s when all other treatments have stopped working.

The petition signed by 98 MPs put pressure on NHS England to act urgently to address the situation.

Laura Cockram, policy and campaigns manager at Parkinson’s UK said: “I am elated that the NHS has finally arrived at this decision. We know this treatment has had transformative effects on many that have been treated with it and how vital it is that those who need Duodopa receive it without delay. This is an important day for Parkinson’s care.”

Last Month

Next Month

Go Back

Share this story

Comments

Advances

5 things you might not know about DBS

Diving deeper into deep brain stimulation with Dr Lennart Stieglitz

Insight into Parkinson’s: “join us as we make history”

We talk to the founder of the ‘Insight into Parkinson’s’ summit

Teenager raises over $40,000 for Parkinson’s research

Jenna Sigurdson, 13, raised more than $40,000 for research into Parkinson's

Investigational Parkinson’s disease dementia therapy fails in clinical trial

Research into new potential therapies for people with Parkinson’s is complex, which means that not all clinical trials will successfully move on to the next phase. This proved to be the case for US biotech company Aptinyx, which announced that it will halt further development work on an investigational therapy following “disappointing” results in the second phase of its study. The research had set out to examine the effect of NYX-458 – an oral therapy created to modulate the activity of receptors in the brain that are responsible for communication between neurons. The aim of the therapy was to improve cognition in people with cognitive impairment linked to Parkinson’s or Lewy body dementia. Yet, when compared to a placebo, the therapy didn’t demonstrate “meaningful improvements” in cognitive function. Dr Andy Kidd, president and CEO at Aptinyx, said: “We are very disappointed that the results of this Phase 2 study did…

A new intimacy guide aims to support people with Parkinson’s disease in the US

Does sexual wellness in the Parkinson’s community need more focus? It’s an area that the American Parkinson Disease Association (APDA) and media brand Havas Health Plus have targeted through the launch of a free intimacy guide. Available to people in the US, ‘The ParkinSex Booklet & Kit’ aims to support those whose relationships may have been impacted by emotional and physical distance linked to the condition. Alongside an educational guide, the kit includes items such as candles, coupons for adaptative clothing and massage stones. Following a positive response to an initial pilot distribution of the guides in the US, there is now a waitlist for future kits. Commenting on the launch in a press release, APDA president and CEO Leslie Chambers said: “The challenges of Parkinson’s can often result in intimacy and connection getting left behind. This is why we created ‘The ParkinSex Booklet & Kit’, to help people with…

How prevalent are non-visual hallucinations in Parkinson’s disease?

Some people in the later stages of Parkinson’s can experience hallucinations – “when you see, hear or feel things that aren’t there”. With most research into this topic centred on visual hallucinations, a team in Australia set out to investigate data around non-visual hallucinations in people with the condition. Published in the ‘Journal of Neurology’, the analysis drew on 91 relevant studies released between 1970 and 2022. The team found that visual hallucinations appeared to be most common, with an expected prevalence of up to 96.6%. Meanwhile, non-visual hallucinations – including auditory (relating to the sense of hearing) and olfactory (relating to the sense of smell) – had an estimated prevalence of up to 73.3%. Concluding that non-visual hallucinations may “impact a notable proportion” of people with the condition, the team said: “More direct research and clinical attention need to be devoted to the study and management of such hallucinatory…

All fields required

First name*
Last name*
Email address*
Enter Email Confirm Email
Country of residence*
About me*
- I have Parkinson's disease
- I am a partner / carer / family / friend of someone who has Parkinson's
- I am a healthcare professional with an interest in Parkinson's
- I work for a Parkinson's disease organisation
- Other
CAPTCHA
*
- By proceeding you agree to our
Name
This field is for validation purposes and should be left unchanged.

NHS England to fund Duodopa

News

Author: Parkinson's Life editorsPublished: 28 August 2015

Prep: Cook: Serves:

Last Month

Next Month

Share this story

Comments

sponsored article

Advances

5 things you might not know about DBS

Interviews

Insight into Parkinson’s: “join us as we make history”

Global update

Teenager raises over $40,000 for Parkinson’s research

Investigational Parkinson’s disease dementia therapy fails in clinical trial

A new intimacy guide aims to support people with Parkinson’s disease in the US

How prevalent are non-visual hallucinations in Parkinson’s disease?

{title}

Subscribe

NHS England to fund Duodopa

News

Author: Parkinson's Life editorsPublished: 28 August 2015

Last Month

Next Month

Share this story

Comments

Related articles

sponsored article

Advances

5 things you might not know about DBS

Interviews

Insight into Parkinson’s: “join us as we make history”

Global update

Teenager raises over $40,000 for Parkinson’s research

Investigational Parkinson’s disease dementia therapy fails in clinical trial

A new intimacy guide aims to support people with Parkinson’s disease in the US

How prevalent are non-visual hallucinations in Parkinson’s disease?

{title}

Subscribe

Sign in